mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2020-1-118-124mrj-1002Research ArticleИНФОРМАЦИЯINFORMATIONXXVII Конгресс Международного общества по тромбозу и гемостазу27th Congress of the International Society on Thrombosis and HemostasisСередавкинаН. В.SeredavkinaN. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow, 115522

n_seredavkina@mail.ruФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatogyRussian Federation202021032020141118124Copyright © Середавкина Н.В., 20202020Середавкина Н.В.Seredavkina N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1002

В статье представлена информация о XXVII Конгрессе Международного общества по тромбозам и гемостазу, состоявшемся в июле 2019 г. в Мельбурне (Австралия). Это ведущий в мире форум по тромбозу и гемостазу, а также по причинам кровотечений и их клиническим проявлениям. Он объединяет всех специалистов, которые по роду своей деятельности имеют отношение к этой проблеме.

The paper presents information on the 27th Congress of the International Society on Thrombosis and Hemostasis, which was held in Melbourne (Australia) in July 2019. This congress is the world’s leading forum on thrombosis and hemostasis, as well as on the causes of bleeding and their clinical manifestations. It unites all specialists who are relevant to this problem.

XXVII Конгресс Международного общества по тромбозу и гемостазу27th Congress of the International Society on Thrombosis and HemostasisReferencesMedcalf R. Message from the ISTH 2019 Congress President. ISTH 2019 Final program. 2019. P. 4-5.Medcalf R. Message from the ISTH 2019 Congress President. ISTH 2019 Final program. 2019. P. 4-5.McLintock C. Message from the ISTH President. ISTH 2019 Final program. 2019. P. 6-7.McLintock C. Message from the ISTH President. ISTH 2019 Final program. 2019. P. 6-7.Moulinet T, Dufrost V, Clerc-Urmes I, et al. Predictive value of thrombocytopenia in antiphospholipid syndrome. ISTH 2019 Final program. 2019; OC 23.4. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497Medcalf R. Message from the ISTH 2019 Congress President. ISTH 2019 Final program. 2019. P. 4-5.Sato T, Amengual O, Fujieda Y, et al. IgM antiphospholipid antibodies: long term follow-up ant thrombotic risk. ISTH 2019 Final program. 2019; OC 23.3. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497McLintock C. Message from the ISTH President. ISTH 2019 Final program. 2019. P. 6-7.Ohnishi N, Fujieda Y, Kono M, et al. The prothrombin/MHC class II complex on procoagulant cells as the novel immune target for pathogenic antiphospholipid syndrome. ISTH 2019 Final program. 2019; OC 23.5. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1 497Moulinet T, Dufrost V, Clerc-Urmes I, et al. Predictive value of thrombocytopenia in antiphospholipid syndrome. ISTH 2019 Final program. 2019; OC 23.4. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497Dufrost V, Reshetnyak T, Satybaldyeva M, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data metaanalysis. ISTH 2019 Final program. 2019; OC 23.1. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497Sato T, Amengual O, Fujieda Y, et al. IgM antiphospholipid antibodies: long term follow-up ant thrombotic risk. ISTH 2019 Final program. 2019; OC 23.3. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497Yin D, Chayoua W, De Laat B, et al. Detection of anti-domain I antibodies enables the identification of high-risk antiphospholipid syndrome patients: results of a multicenter study. ISTH 2019 Final program. 2019; OC 23.2. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497Ohnishi N, Fujieda Y, Kono M, et al. The prothrombin/MHC class II complex on procoagulant cells as the novel immune target for pathogenic antiphospholipid syndrome. ISTH 2019 Final program. 2019; OC 23.5. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1 497Zuily S. What is the association between antiphospholipid antibodies and disseminated intravascular coagulation during pregnancy or postpartum period? Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.Dufrost V, Reshetnyak T, Satybaldyeva M, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data metaanalysis. ISTH 2019 Final program. 2019; OC 23.1. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497Griffin J. The multiple function of protein C and its potential as a therapeutic target. Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.Yin D, Chayoua W, De Laat B, et al. Detection of anti-domain I antibodies enables the identification of high-risk antiphospholipid syndrome patients: results of a multicenter study. ISTH 2019 Final program. 2019; OC 23.2. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497Brandao L. Clinical presentation and diagnosis of protein C deficiency. Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.Zuily S. What is the association between antiphospholipid antibodies and disseminated intravascular coagulation during pregnancy or postpartum period? Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.Monagle P. Acute- and long-term management of protein C deficiency. Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.Griffin J. The multiple function of protein C and its potential as a therapeutic target. Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.Siegal DM. Timing and management of patients needing urganr and emergent procedures: PAUSE ER Study. Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.Brandao L. Clinical presentation and diagnosis of protein C deficiency. Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.Hendriks SV, Bavalia R, Van Bemmel T, et al. Current practice patterns of outpatient management of acute pulmonary embolism: a post-hoc analysis of the year study. ISTH 2019 Final program. 2019; OC 14.1. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1 497Monagle P. Acute- and long-term management of protein C deficiency. Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.Van der Wall SJ, Hendriks SV, Huisman MV, Klok FA. Home treatment of acute pulmonary embolism: state of the art in 2018. Curr Opin Pulm Med. 2018;24(5):425-31. doi: 10.1097/MCP.0000000000000512 15. Rodger M. Recurrent VTE on anticoagulant therapy: what next? Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.Siegal DM. Timing and management of patients needing urganr and emergent procedures: PAUSE ER Study. Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.Galkov M, Sidorova M, Kiseleva E, Gorbacheva L. New peptide – agonist of PAR1 demonstrates neuroprotective effect at the photothrombosis – induced damage of mouse brain. ISTH 2019 Final program. 2019; OC 02.5. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497Hendriks SV, Bavalia R, Van Bemmel T, et al. Current practice patterns of outpatient management of acute pulmonary embolism: a post-hoc analysis of the year study. ISTH 2019 Final program. 2019; OC 14.1. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1 497Iastrebova E, Konokhova A, Strokotov D, Maltsev V. Role of erythrocyte gas transport function in the destabilization of atherosclerotic plaque. ISTH 2019 Final program. 2019; OC 12.4. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497Van der Wall SJ, Hendriks SV, Huisman MV, Klok FA. Home treatment of acute pulmonary embolism: state of the art in 2018. Curr Opin Pulm Med. 2018;24(5):425-31. doi: 10.1097/MCP.0000000000000512 15. Rodger M. Recurrent VTE on anticoagulant therapy: what next? Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.Panteleev M. Hemodynamics: wall shear rate/blood flow values in human and mouse vessels. Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.Galkov M, Sidorova M, Kiseleva E, Gorbacheva L. New peptide – agonist of PAR1 demonstrates neuroprotective effect at the photothrombosis – induced damage of mouse brain. ISTH 2019 Final program. 2019; OC 02.5. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497Shibeko AM, Chopard B, Hoekstra AG, Panteleev MA. Fibrin clot resistance to thrombolytic therapy is controlled by bypassing flow through collateral vessels, clot permeability and PAI-1 level. ISTH 2019 Final program. 2019; OC 17.4. Available from: рttps://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497Iastrebova E, Konokhova A, Strokotov D, Maltsev V. Role of erythrocyte gas transport function in the destabilization of atherosclerotic plaque. ISTH 2019 Final program. 2019; OC 12.4. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497Satybaldyeva MA, Seredavkina NV, Nasonov EL, et al. Dabigatran for failed warfarin treatment in high-risk patients with antiphospholipid syndrome. ISTH 2019 Final program. 2019; PB 1097. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497Panteleev M. Hemodynamics: wall shear rate/blood flow values in human and mouse vessels. Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.Shibeko AM, Chopard B, Hoekstra AG, Panteleev MA. Fibrin clot resistance to thrombolytic therapy is controlled by bypassing flow through collateral vessels, clot permeability and PAI-1 level. ISTH 2019 Final program. 2019; OC 17.4. Available from: рttps://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497Shibeko AM, Chopard B, Hoekstra AG, Panteleev MA. Fibrin clot resistance to thrombolytic therapy is controlled by bypassing flow through collateral vessels, clot permeability and PAI-1 level. ISTH 2019 Final program. 2019; OC 17.4. Available from: рttps://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497Satybaldyeva MA, Seredavkina NV, Nasonov EL, et al. Dabigatran for failed warfarin treatment in high-risk patients with antiphospholipid syndrome. ISTH 2019 Final program. 2019; PB 1097. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497Satybaldyeva MA, Seredavkina NV, Nasonov EL, et al. Dabigatran for failed warfarin treatment in high-risk patients with antiphospholipid syndrome. ISTH 2019 Final program. 2019; PB 1097. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497

The authors declare that there are no conflicts of interest present.